Back to All Events
*This event is for informational purposes only and is intended solely for accredited investors. The content shared by participating fund managers does not constitute an offer to sell or a solicitation of an offer to buy any securities. All investment opportunities must be evaluated independently and comply with applicable securities laws.
🚨 For accredited investors only. To verify your status, please check the SEC Regulations here.
What to Expect:
We will spotlight three VCs who will share their fund strategy, investment focus, portfolio highlights, and what they look for in LP partners.
Following the spotlight, attendees will be able to join interactive breakout sessions hosted by each VC — a chance to dive deeper, ask questions, and explore potential alignment in a more intimate setting.
Whether you're an experienced LP and exploring new fund opportunities or an accredited investor wanting to learn more about becoming an LP, this event offers a rare window into the minds and models of top investors.
🔥 Meet the Fund Managers:
Cat Middleton, General Partner of The Venture Collective, a transformational, early-stage venture firm backed by world class entrepreneurs and business leaders. Led by a seasoned team of venture investors, ex-founders, and investment management executives, we invest our capital, time, and network into highly defensible, fast-growing companies with the potential to solve the world’s largest problems.
Cvic Innocent, General Partner of Frankenbuild Ventures, a MA-based VC firm investing in companies building hardtech, and hardware-enabled AI, for climate tech. This includes space frontier, blue economy, infrastructure tech, & the green solutions crossing them all.
Michele Colucci, Managing Partner of DigitalDx Ventures, a majority woman-owned impact fund comprised of a team of successful Silicon Valley digital health investors, medical and legal professionals leveraging AI and big data technologies to diagnose major global health issues such as breast and other cancers, cardiovascular and kidney health, Alzheimer's disease, and mental health with a particular focus on: 1. Enabling early, more accurate detection; 2. Minimizing invasiveness; 3. Expanding access to treatment (through lowered costs).